Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Convincing evidence from placebo-referenced randomized controlled trials supports efficacy for clomipramine and selective serotonin reuptake inhibitors for acute treatment of obsessive-compulsive disorder. It remains less conclusively understood whether these agents maintain efficacy over the longer term. This paper systematically reviews long-term medication studies in obsessive-compulsive disorder. Studies of clomipramine, fluoxetine and sertraline investigated 'responders' from acute treatment trials and extended treatment up to 12 months versus placebo. Responses to medication were sustained. A 24-week placebo-controlled trial of escitalopram (10 mg or 20 mg/day) and paroxetine (40 mg/day) demonstrated ongoing efficacy for all three treatments. Studies that randomized treated cases to placebo demonstrated reemergence of symptoms in the placebo-treated cohort. Six relapse prevention trials were found by systematic search. Some, but not all, revealed significant advantages for remaining on medication. Paroxetine (20-60 mg/day) and escitalopram (10 or 20 mg/day) were each found to outperform placebo in preventing relapse during 24 weeks of double-blind, randomized follow-up. Meta-analysis, using Review Manager software (4.2.8), detected overall superiority of selective serotonin reuptake inhibitors to placebo in preventing relapse among adult treatment-responders. Worsening by five Yale-Brown Obsessive Compulsive Scale points emerged from the review as a suggested threshold for relapse. Viewed collectively, these results suggest that selective serotonin reuptake inhibitors are effective long-term treatments and relapse prevention represents the treatment target for obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Eddy, K. T., Dutra, L., Bradley, R., & Westen, D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.08.004 · Cited by 475 · cited 1×
“Studies to date have chosen various remission thresholds ranging from a total Y-BOCS score < 16, which has since been criticized as being too high (Simpson et al., 2006), to Y-BOCS r 7 (Van Oppen et al., 1995; Cottraux et al., 2001; Hollander et al., 2003; Eddy et al., 2004).”
BackgroundClomipramine Treatment of Childhood Obsessive-Compulsive Disorder: A Double-blind Controlled Study
Flament, M. F. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330057007 · Cited by 466
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Self-citationPinto, A., Mancebo, M. C., Eisen, J. L., Pagano, M. E., & Rasmussen, S. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0503 · Cited by 386 · cited 4×
“OCD in a large clinical sample collected data between June 2001 and October 2004 for 293 adult participants with a primary diagnosis of DSM-IV OCD, who had sought treatment for the disorder (Pinto et al., 2006).”
BackgroundInfluentialCognitive therapy and exposure in vivo in the treatment of obsessive–compulsive disorder
Van Oppen, P., De Haan, E., Van Balkom, A. J. L. M., Spinhoven, P., Hoogduin, K., & Van Dyck, R. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)00052-l · Cited by 350 · cited 1×
“Studies to date have chosen various remission thresholds ranging from a total Y-BOCS score < 16, which has since been criticized as being too high (Simpson et al., 2006), to Y-BOCS r 7 (Van Oppen et al., 1995; Cottraux et al., 2001; Hollander et al., 2003; Eddy et al., 2004).”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Self-citation(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301 · cited 2×
“Using different SRIs and different methodologies and criteria, relapse rates following discontinuation ranged from around 24% over 28 weeks (Koran et al., 2002) to 89% over 7 weeks (Pato et al., 1988).”
BackgroundMethodCottraux, J., Note, I., Yao, S. N., Lafont, S., Note, B., Mollard, E., Bouvard, M., Sauteraud, A., Bourgeois, M., & Dartigues, J.-F. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056269 · Cited by 298 · cited 1×
“Studies to date have chosen various remission thresholds ranging from a total Y-BOCS score < 16, which has since been criticized as being too high (Simpson et al., 2006), to Y-BOCS r 7 (Van Oppen et al., 1995; Cottraux et al., 2001; Hollander et al., 2003; Eddy et al., 2004).”
Background
Cited by
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Self-citationHudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Self-citationFineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Self-citationPharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“…the Sheehan Disability Scale (SDS); and Short Form (SF-36), respectively, in two prospective, randomised, placebo-controlled trials of escitalopram (Fineberg et al., 2007b; Stein et al., 2007), suggest that SSRI is associated with clinically relevant improvements in HR-QoL in OCD (Hollander et…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Fineberg, N. A., Pampaloni, I., Pallanti, S., Ipser, J., & Stein, D. J.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-11
- Volume
- 22
- Issue
- 6
- Pages
- 313-322
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2030024577
- Cited by
- 48
- References
- 13
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.